Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes
Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing frequency of these weekly basal injections from seven to one per week1Awiqli® will be available at over 70,000
Novo Nordisk released a new insulin medicine that people with type 2 diabetes only need to inject once a week instead of every day. This is a new product option that might help the company, so watch whether doctors and patients start using it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.